IL143485A0 - Non-myeloablative tolerogenic treatment - Google Patents

Non-myeloablative tolerogenic treatment

Info

Publication number
IL143485A0
IL143485A0 IL14348599A IL14348599A IL143485A0 IL 143485 A0 IL143485 A0 IL 143485A0 IL 14348599 A IL14348599 A IL 14348599A IL 14348599 A IL14348599 A IL 14348599A IL 143485 A0 IL143485 A0 IL 143485A0
Authority
IL
Israel
Prior art keywords
tolerogenic treatment
myeloablative
myeloablative tolerogenic
treatment
tolerogenic
Prior art date
Application number
IL14348599A
Other languages
English (en)
Original Assignee
Hadasit Med Res Service
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Med Res Service, Baxter Int filed Critical Hadasit Med Res Service
Publication of IL143485A0 publication Critical patent/IL143485A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Husbandry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14348599A 1998-12-31 1999-12-23 Non-myeloablative tolerogenic treatment IL143485A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/222,011 US6428782B1 (en) 1997-05-23 1998-12-31 Non-myeloablative tolerogenic treatment
PCT/US1999/030704 WO2000040701A2 (en) 1998-12-31 1999-12-23 Non-myeloablative tolerogenic treatment

Publications (1)

Publication Number Publication Date
IL143485A0 true IL143485A0 (en) 2002-04-21

Family

ID=22830367

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14348599A IL143485A0 (en) 1998-12-31 1999-12-23 Non-myeloablative tolerogenic treatment

Country Status (6)

Country Link
US (1) US6428782B1 (enExample)
EP (3) EP1141246A2 (enExample)
JP (1) JP2002534083A (enExample)
CA (1) CA2356434A1 (enExample)
IL (1) IL143485A0 (enExample)
WO (1) WO2000040701A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL140796A0 (en) * 2001-01-08 2002-02-10 Hadasit Med Res Service An autologous anti-cancer vaccine
JP3734461B2 (ja) 2001-08-08 2006-01-11 松下電器産業株式会社 ライセンス情報変換装置
WO2003038048A2 (en) * 2001-10-30 2003-05-08 The United States Of America As Represented By The Secretary Of The Navy Ex-vivo rescue of transplantable hematopoietic stem cells following myeloablative injury
AU2002952834A0 (en) * 2002-09-16 2002-12-05 The Walter And Eliza Hall Institute Of Medical Research A method of treating an autoimmune disease
WO2005021734A2 (en) * 2003-09-02 2005-03-10 University Of Massachussets Generation of hematopoietic chimerism and induction of central tolerance
MX2008000974A (es) * 2005-07-22 2008-03-27 Univ California Composiciones de heparina e inhibicion de selectina.
EP2345412A1 (en) * 2005-12-02 2011-07-20 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs for treating immune disorders
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2008034071A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Method of identifying patients suitable for high-dose cyclophosphamide treatment
WO2008034074A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclosphosphamide in combination with anti-idiotypic vaccines
US9026372B2 (en) * 2007-11-21 2015-05-05 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
WO2009067690A2 (en) * 2007-11-21 2009-05-28 Accentia Biopharmaceuticals, Inc. Methods for safe and effective treatment using oxazaphosphorine drugs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273738A (en) 1990-03-03 1993-12-28 Fred Hutchinson Cancer Research Center Radiation delivery to lymphoid and marrow tissues
PT621786E (pt) 1992-01-08 2002-07-31 Gen Hospital Corp Inducao da tolerancia a xenoenxertos
US5876708A (en) 1992-02-19 1999-03-02 The General Hospital Corporation Allogeneic and xenogeneic transplantation
US5589582A (en) 1992-10-27 1996-12-31 Biotransplant, Inc. Polynucleotides en coding porcine cytokines
AU7404494A (en) 1993-07-21 1995-02-20 Cellpro, Incorporated Methods and compositions for preventing immune rejection of solid organ grafts
ATE188487T1 (de) * 1993-09-02 2000-01-15 Dartmouth College Anti-gp39 antikoerper und deren verwendungen
US5635156A (en) 1993-09-13 1997-06-03 University Of Pittsburgh Non-lethal methods for conditioning a recipient for bone marrow transplantation
US5514364A (en) 1993-09-13 1996-05-07 University Of Pittsburgh Non-lethal methods for conditioning a recipient for bone marrow transplantation
IL112969A (en) * 1994-03-17 2001-05-20 Baxter Int Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
WO1996031229A1 (en) * 1995-04-05 1996-10-10 Beth Israel Hospital Association Inhibiting rejection of a graft
WO1996037208A1 (en) 1995-05-25 1996-11-28 Baxter International Inc. Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
US6544787B1 (en) * 1996-11-15 2003-04-08 Hadash Medical Research Services And Development Ltd. Non-myeloablative/lymphoablative conditioning regimen to induce patient anti-donor unresponsiveness in stem cell transplantation
EP0983074B1 (en) * 1997-05-23 2003-07-30 Hadasit Medical Research Services And Development Ltd. Non-myeloablative tolerogenic treatment

Also Published As

Publication number Publication date
EP1498136A8 (en) 2005-04-13
WO2000040701A9 (en) 2001-09-13
WO2000040701A3 (en) 2000-12-21
US6428782B1 (en) 2002-08-06
EP1498479A2 (en) 2005-01-19
CA2356434A1 (en) 2000-07-13
EP1498136A2 (en) 2005-01-19
EP1141246A2 (en) 2001-10-10
WO2000040701A2 (en) 2000-07-13
JP2002534083A (ja) 2002-10-15

Similar Documents

Publication Publication Date Title
GB2321193B (en) Endoscopic treatment tool
IL128850A0 (en) Medical treatment
GB9804885D0 (en) Therapeutic combination
GB9800942D0 (en) Well treatment
GB9700899D0 (en) Novel treatment
IL143485A0 (en) Non-myeloablative tolerogenic treatment
ZA978359B (en) Novel treatment
ZA976593B (en) Novel treatment
GB9608657D0 (en) Novel treatment
IL132845A0 (en) Non-myeloablative tolerogenic treatment
GB0020261D0 (en) Therapeutic treatment
GB9818524D0 (en) Inorgasmia treatment
GB9815497D0 (en) Treatment
GB9721692D0 (en) Novel treatment
GB9625795D0 (en) Novel treatment
GB9612752D0 (en) Novel treatment
GB9828550D0 (en) Treatment
GB9721693D0 (en) Novel treatment
GB9716742D0 (en) Treatment
GB9812914D0 (en) Treatment
GB9804442D0 (en) Novel treatment
GB9617762D0 (en) Treatment
GB9616412D0 (en) Novel treatment
GB9614740D0 (en) Novel treatment
GB9616409D0 (en) Novel treatment

Legal Events

Date Code Title Description
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees